• Policy
• Expansion of benefit standards such as Tenofovir/Baricitinib
• by Kim, Jung-Ju Apr 24, 2022 06:33pm

• Policy
• Expanding the use of Paxlovid with underlying dz over 12 yrs
• by Lee, Jeong-Hwan Apr 20, 2022 06:05am

• Policy
• MFDS requested supplementary data of Mifepristone
• by Lee, Hye-Kyung Apr 19, 2022 05:52am

• Policy
• Reimb. suspension on rebate drugs unconstitutional
• by Lee, Tak-Sun Apr 18, 2022 05:58am

• Policy
• Utilizing RWD for Re-evaluation of Old Drugs
• by Lee, Hye-Kyung Apr 18, 2022 05:58am

• Policy
• Will losses from drug price cut dispositions be recovered?
• by Lee, Jeong-Hwan Apr 15, 2022 06:03am

• Policy
• Omicron recombinant XL mutation found in Korea
• by Lee, Jeong-Hwan Apr 14, 2022 05:56am

• Policy
• P3T for Roche’s Giredestrant was approved in Korea
• by Lee, Hye-Kyung Apr 14, 2022 05:56am

• Policy
• Why Galvusmet is priced same as salt-modified and generics
• by Lee, Tak-Sun Apr 13, 2022 06:03am

• Policy
• Korea loses $9 billion a year in exports
• by Lee, Jeong-Hwan Apr 13, 2022 06:02am